Announcement of Data from the Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases On October 12, 2026, Mirum…
Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement of Data from the Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases On October 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced topline results from the Phase 3 EXPAND study evaluating LIVMAR
How this was made
The 30-second read
Why it matters
The 8-K provides first-read topline efficacy and safety signals, plus a stated plan to submit a supplemental NDA in the first half of 2027, which can shift probability-weighted valuation for regulatory success.
Market read
Statistically significant itch and bile-acid improvements with no new safety signals, plus an explicit supplemental NDA timing, are the core tradable catalysts.
What to watch
Safety is described as consistent with prior experience, but the trial size is small (52 total), so investors may wait for full datasets, confirmatory analyses, and any FDA feedback ahead of the 1H 2027 supplemental NDA.
Background
Mirum’s LIVMARLI (maralixibat) is being evaluated in the Phase 3 EXPAND study for cholestatic pruritus in ultra-rare cholestatic liver diseases, including biliary atresia.
Ticker impact
Mirum reported topline Phase 3 EXPAND results for LIVMARLI, saying the study met the primary ItchRO(Obs) endpoint and all five secondary endpoints.
Likely upward pressure as traders price in improved probability of approval and near-term regulatory filing momentum.
The filing discloses statistically significant primary and multiple secondary efficacy outcomes, plus no new safety signals, and explicitly states an NDA submission timeline.
Market effects
Reinforces investor appetite for rare-disease hepatology assets and bile-acid pathway therapies, potentially improving sentiment for adjacent clinical-stage programs.
Primarily US biotech sentiment; limited direct regional spillover beyond specialty pharma/biotech indices.
Rare cholestatic pruritus treatment development remains globally relevant, but the disclosed catalyst is company-specific.
Counterpoint
Topline success may not fully de-risk approval; endpoint durability, subgroup consistency, and regulatory interpretation of itch and bile-acid biomarkers can still diverge from trial results.
Key entities
- companyMirum Pharmaceuticals, Inc.
Issuer of the SEC 8-K and developer of LIVMARLI (maralixibat).
- drugLIVMARLI (maralixibat)
Phase 3 EXPAND investigational therapy for cholestatic pruritus in ultra-rare cholestatic liver diseases.
- clinical_trialPhase 3 EXPAND study
Randomized double-blind trial reporting topline results with primary ItchRO(Obs) endpoint and multiple secondary endpoints.
